By George Ongkojoyo 
A landmark study led by researchers from the University of Pennsylvania’s Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center has revealed that the severe shortage of generic platinum chemotherapy drugs in 2023 did not lead to an increase in mortality among patients with advanced cancer. The findings, published this week in the Journal of the National Cancer Institute (JNCI), provide a critical data-driven perspective on a period of intense anxiety within the American oncology community. While the shortages of cisplatin and carboplatin triggered widespread alarm and forced hospitals to ration supplies, the analysis indicates that the overall reduction in prescription rates was less severe than many experts had initially feared.
According to the study, prescription rates for these two essential chemotherapy agents fell by less than three percent overall during the shortage period. Even at the height of the crisis in June 2023, the drop in prescriptions reached 15.1 percent—a significant figure, but one that was mitigated by the rapid adoption of alternative treatment protocols. The research team, led by Dr. Jacob B. Reibel and Dr. Ronac Mamtani, analyzed data from nearly 12,000 adults across the United States, concluding that the clinical resilience of the healthcare system, bolstered by alternative therapies, prevented a catastrophic spike in cancer-related deaths during the supply chain disruption.
The Critical Role of Platinum-Based Chemotherapy
Cisplatin and carboplatin have served as the "backbone" of oncological treatment for over three decades. Cisplatin, first approved by the U.S. Food and Drug Administration (FDA) in 1978, and its later-generation counterpart carboplatin, approved in 1989, are utilized in the treatment of approximately 10 to 20 percent of all cancer patients. Their versatility makes them indispensable for treating a wide array of malignancies, including lung, head and neck, breast, bladder, ovarian, uterine, and testicular cancers.
As generic medications, these drugs are highly cost-effective, providing high-quality care at a fraction of the price of newer, branded immunotherapy or targeted agents. Because they are off-patent, however, the profit margins for manufacturers are thin, which has historically led to a fragile supply chain. When manufacturing interruptions occur, there is often little redundant capacity in the system to absorb the shock, a vulnerability that was laid bare in early 2023.
Chronology of the 2023 Supply Crisis
The crisis began in earnest in February 2023 when the FDA officially added cisplatin to its drug shortage list. The disruption was primarily traced back to a manufacturing facility in India operated by Intas Pharmaceuticals. Following an FDA inspection that revealed significant quality control failures, the plant suspended production, cutting off a primary source of cisplatin for the U.S. market.
The ripple effect was immediate. As oncologists shifted patients from cisplatin to carboplatin to maintain treatment schedules, the increased demand quickly overwhelmed the supply of carboplatin. By April 2023, the FDA announced a shortage of carboplatin as well. This created a dual-crisis scenario where the two most common chemotherapy agents were simultaneously unavailable or strictly rationed.
By June 2023, the shortage reached its peak. National surveys conducted by the National Comprehensive Cancer Network (NCCN) at that time reported that 93 percent of cancer centers were experiencing a shortage of carboplatin, and 70 percent were short on cisplatin. This prompted major national oncology societies, including the American Society of Clinical Oncology (ASCO), to issue emergency guidance on how to prioritize patients for treatment and which alternative regimens to utilize.
Analyzing the Impact: Data and Methodology
To understand the real-world consequences of these shortages, the Penn Medicine research team conducted a retrospective cohort study. They analyzed the records of 11,797 adults across the U.S. diagnosed with advanced solid cancers for which platinum chemotherapy is the recommended first-line therapy. The study compared patients who began treatment during the one-year period before the shortage (February 2022 to January 2023) with those who began treatment during the shortage period (February 2023 to January 2024).
The researchers focused specifically on patients with advanced, non-curable cancers. This demographic was chosen because, during the height of the shortage, clinical guidelines recommended prioritizing the limited supply of platinum drugs for patients with curable cancers (such as testicular cancer or early-stage lung cancer). Therefore, patients with advanced disease were theoretically the most likely to be transitioned to alternative, non-platinum treatments.
The data revealed that from February 2023 through January 2024, there was a 2.7 percent decrease in the use of platinum chemotherapy compared to the previous year. In the specific cohort studied, this represented 137 fewer patients receiving the drugs than expected. When extrapolated nationwide, the researchers estimate that approximately 1,000 patients with advanced cancer were affected by the shortage.
Despite this reduction in the "gold standard" treatment, the study found no statistically significant difference in mortality rates. With a median follow-up time of 7.6 months after beginning treatment, the survival outcomes for patients during the shortage were comparable to those in the pre-shortage era.
The Role of Alternative Therapies and "Financial Toxicity"
The lack of an increase in mortality is largely attributed to the availability of modern alternative therapies. Over the last decade, the oncology field has seen the emergence of immune checkpoint inhibitors and highly specific targeted therapies. While platinum chemotherapy remains the first choice for many cancers due to its proven efficacy and low cost, these newer drugs provided a viable safety net.
However, the researchers cautioned that the shift to alternative medications is not without consequences. "We always want to prioritize the best treatments that we have for patients, and platinum chemotherapies just happen to also be very cost-effective because they’re generic and have been around for decades," said senior author Dr. Ronac Mamtani.
The study highlighted several potential drawbacks of using alternatives:
- Financial Burden: Branded immunotherapies and targeted drugs can cost tens of thousands of dollars more per course of treatment than generic platinum drugs. This "financial toxicity" can strain hospital budgets and increase out-of-pocket costs for patients.
- Side Effect Profiles: Different drugs come with different risks. While cisplatin is known for potential kidney toxicity and hearing loss, immunotherapies can cause unique immune-related adverse events that require different management strategies.
- Standard of Care Deviations: Even if mortality was not immediately affected, the inability to provide the established standard of care represents a failure in the healthcare delivery system.
Official Responses and Regulatory Intervention
The severity of the 2023 shortage forced the FDA to take the unusual step of allowing the temporary importation of cisplatin from Qilu Pharmaceutical, a manufacturer in China not previously authorized to sell the drug in the U.S. This emergency measure, along with increased production from other domestic and international suppliers, helped to slowly stabilize the market.
By the end of June 2024, the FDA officially listed the cisplatin shortage as resolved. While carboplatin technically remains on the FDA’s shortage list as of late 2024, the Penn Medicine research team noted that prescribing levels have effectively returned to pre-crisis norms.
The crisis has sparked a broader debate in Washington regarding the resilience of the generic drug supply chain. Lawmakers and healthcare advocates have called for greater transparency in drug manufacturing locations and the creation of strategic reserves for essential generic medicines. The fact that a single factory inspection in India could disrupt the treatment of thousands of American cancer patients has been cited as a significant national security and public health concern.
Implications for Future Oncology Practice
The Penn Medicine study provides a degree of reassurance that the clinical impact of the 2023 shortage was mitigated by proactive medical management. However, the authors emphasize that the goal should be to prevent such shortages from occurring in the first place.
"When we looked at the data on prescribing practices over the shortage period, compared to the previous year, we found that although reporting of the shortages was widespread, it didn’t affect as many patients as we had feared," said lead author Dr. Jacob B. Reibel. He added, however, that even a small number of patients being denied preferred treatments due to supply chain issues is unacceptable in a modern healthcare system.
The study, which was funded by the National Institutes of Health, serves as a vital record of the 2023 platinum chemotherapy crisis. It underscores the importance of having a diverse arsenal of oncological treatments but also highlights the precarious nature of the generic drug market. As the healthcare industry moves forward, the lessons learned from the "platinum gap" of 2023 will likely inform new strategies for drug procurement, patient prioritization, and the long-term stabilization of the life-saving generic medications that remain the foundation of cancer care.